Description: Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Home Page: www.ono-pharma.com
8-2, Kyutaromachi 1-chome
Osaka,
541-8564
Japan
Phone:
81 6 6263 5670
Officers
| Name | Title |
|---|---|
| Mr. Gyo Sagara | CEO, Pres & Representative Director |
| Mr. Shozo Matsuoka Ph.D. | Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA |
| Yukio Tani | Corp. Exec. Officer & Head of Corp. Communications |
| Katsuji Teranishi | Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div. |
| Mr. Isao Ono | Exec. Officer, Director of Corp. Research & Director |
| Mr. Hiroshi Ichikawa | Corp. Officer & Sr. Director of Medical External Affairs |
| Mr. Toichi Takino Ph.D. | Sr. Exec. Officer, Exec. Director of Discovery & Research and Director |
| Mr. Toshihiro Tsujinaka | Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director |
| Hiromu Habashita Ph.D. | Corp. Officer and Deputy Exec. Director of Discovery & Research Division |
| Kiyoaki Idemitsu | Exec. Officer, Exec. Director of Clinical Devel. & Director |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 11.8343 |
|---|---|
| Trailing PE: | 14.5 |
| Price-to-Book MRQ: | 2.3444 |
| Price-to-Sales TTM: | 0.0303 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 3687 |